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Abstract
© 2017 Ivanova, Khaiboullina, Gomzikova, Martynova, Ferreira, Garanina, Sakhapov, Lomakin,
Khaibullin, Granatov, Khabirov, Rizvanov, Gabibov and Belogurov. Multiple sclerosis (MS) is an
autoimmune disease characterized by demyelination and consequent neuron injury. Although
the pathogenesis  of  MS is  largely  unknown,  a  breach in  immune self-tolerance to  myelin
followed by development of autoreactive encephalitogenic T cells is  suggested to play the
central role. The myelin basic protein (MBP) is believed to be one of the main targets for
autoreactive  lymphocytes.  Recently,  immunodominant  MBP peptides  encapsulated  into  the
mannosylated  liposomes,  referred  as  Xemys,  were  shown  to  suppress  development  of
experimental autoimmune encephalomyelitis, a rodent model of MS, and furthermore passed
the  initial  stage  of  clinical  trials.  Here,  we investigated  the  role  of  individual  polypeptide
components  [MBP  peptides  46-62  (GH17),  124-139  (GK16),  and  147-170  (QR24)]  of  this
liposomal  peptide therapeutic  in  cytokine release and activation of  immune cells  from MS
patients  and  healthy  donors.  The  overall  effects  were  assessed  using  peripheral  blood
mononuclear cells (PBMCs), whereas alterations in antigen-presenting capacities were studied
utilizing  plasmacytoid  dendritic  cells  (pDCs).  Among  three  MBP-immunodominant  peptides,
QR24 and GK16 activated leukocytes, while GH17 was characterized by an immunosuppressive
effect. Peptides QR24 and GK16 upregulated CD4 over CD8 T cells and induced proliferation of
CD25 + cells, whereas GH17 decreased the CD4/CD8 T cell ratio and had limited effects on
CD25  +  T  cells.  Accordingly,  components  of  liposomal  peptide  therapeutic  differed  in
upregulation of cytokines upon addition to PBMCs and pDCs. Peptide QR24 was evidently more
effective in upregulation of pro-inflammatory cytokines, whereas GH17 significantly increased
production of IL-10 through treated cells. Altogether, these data suggest a complexity of action
of the liposomal peptide therapeutic that does not seem to involve simple helper T cells (Th)-
shift but rather the rebalancing of the immune system.
http://dx.doi.org/10.3389/fimmu.2017.01335
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